Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease
AIMS: Type II secretory phospholipase A(2) (sPLA(2)-IIA) is widely expressed in various cell types and may trigger local inflammatory responses. We sought to evaluate whether systemic sPLA(2) is associated with prognosis in patients with coronary heart disease (CHD).
METHODS AND RESULTS: Plasma concentrations of sPLA(2) (ELISA) and sPLA(2) activity (selective fluorometric assay) were measured at baseline in a cohort of 1024 patients aged 30-70 years with CHD. The Cox-proportional hazards model was used to determine the prognostic value of sPLA(2) on a combined cardiovascular disease (CVD) endpoint after adjustment for covariates. During a mean follow-up of 4.1 years, 93 patients (9.1%) experienced a secondary CVD event. In a multivariable model, sPLA(2) mass and activity were associated with hazard ratios of secondary CVD events of 2.07 (95% CI, 1.17-3.66) and 1.65 (95% CI 0.96-2.84) for mass and activity, respectively, when extreme tertiles were compared. Further adjustment for cystatin C, N-terminal-probrain natriuretic peptide, C-reactive protein, and lipoprotein-associated phospholipase A(2) attenuated the associations, still showing a positive trend for mass but a less clear pattern for activity. However, when sPLA(2) mass and activity were analysed as continuous variables both still showed a statistically significant increase in risk in all models.
CONCLUSION: Secretory phospholipase A(2) mass and activity appear to be predictive of secondary CVD events in patients with CHD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
European heart journal - 30(2009), 22 vom: 22. Nov., Seite 2742-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koenig, Wolfgang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.1.1.4 |
|---|
| Anmerkungen: |
Date Completed 26.05.2010 Date Revised 16.11.2009 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehp302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM190563923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM190563923 | ||
| 003 | DE-627 | ||
| 005 | 20231223185541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehp302 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0635.xml |
| 035 | |a (DE-627)NLM190563923 | ||
| 035 | |a (NLM)19666896 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koenig, Wolfgang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2010 | ||
| 500 | |a Date Revised 16.11.2009 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIMS: Type II secretory phospholipase A(2) (sPLA(2)-IIA) is widely expressed in various cell types and may trigger local inflammatory responses. We sought to evaluate whether systemic sPLA(2) is associated with prognosis in patients with coronary heart disease (CHD) | ||
| 520 | |a METHODS AND RESULTS: Plasma concentrations of sPLA(2) (ELISA) and sPLA(2) activity (selective fluorometric assay) were measured at baseline in a cohort of 1024 patients aged 30-70 years with CHD. The Cox-proportional hazards model was used to determine the prognostic value of sPLA(2) on a combined cardiovascular disease (CVD) endpoint after adjustment for covariates. During a mean follow-up of 4.1 years, 93 patients (9.1%) experienced a secondary CVD event. In a multivariable model, sPLA(2) mass and activity were associated with hazard ratios of secondary CVD events of 2.07 (95% CI, 1.17-3.66) and 1.65 (95% CI 0.96-2.84) for mass and activity, respectively, when extreme tertiles were compared. Further adjustment for cystatin C, N-terminal-probrain natriuretic peptide, C-reactive protein, and lipoprotein-associated phospholipase A(2) attenuated the associations, still showing a positive trend for mass but a less clear pattern for activity. However, when sPLA(2) mass and activity were analysed as continuous variables both still showed a statistically significant increase in risk in all models | ||
| 520 | |a CONCLUSION: Secretory phospholipase A(2) mass and activity appear to be predictive of secondary CVD events in patients with CHD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Group II Phospholipases A2 |2 NLM | |
| 650 | 7 | |a EC 3.1.1.4 |2 NLM | |
| 700 | 1 | |a Vossen, Carla Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mallat, Ziad |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Hermann |e verfasserin |4 aut | |
| 700 | 1 | |a Benessiano, Joëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Rothenbacher, Dietrich |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 30(2009), 22 vom: 22. Nov., Seite 2742-8 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2009 |g number:22 |g day:22 |g month:11 |g pages:2742-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehp302 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2009 |e 22 |b 22 |c 11 |h 2742-8 | ||